Mexico vs Senegal: Average cost of drugs for extensively drug-resistant tuberculosis
Mexico
3,500 constant 2022 US$
in 2024
Senegal
3,428 constant 2022 US$
in 2024
Mexico rank
19th
Senegal rank
20th
Average cost of drugs for extensively drug-resistant tuberculosis over time
- Mexico
- Senegal
How they compare
Mexico currently reports 3,500 constant 2022 US$ against 3,428 constant 2022 US$ in Senegal, a difference of 72 constant 2022 US$.
The two have swapped places 2 times across 5 shared years of data; in 2018 it was Mexico ahead.
Mexico ranks 19th and Senegal ranks 20th of 56 countries.
Mexico has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Mexico | Senegal | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 13,881 constant 2022 US$ | 5,308 constant 2022 US$ | 8,573 constant 2022 US$ | Mexico |
| 2020s | 4,351 constant 2022 US$ | 2,890 constant 2022 US$ | 1,461 constant 2022 US$ | Mexico |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of drugs for extensively drug-resistant tuberculosis, Mexico or Senegal?
- Mexico, at 3,500 constant 2022 US$ against 3,428 constant 2022 US$ in Senegal as of 2024.
- What is the difference in average cost of drugs for extensively drug-resistant tuberculosis between Mexico and Senegal?
- 72 constant 2022 US$, with Mexico ahead.
- How many years of comparable data are there for Mexico and Senegal?
- 5 years are reported by both, from 2018 to 2024.
- How do Mexico and Senegal rank globally for average cost of drugs for extensively drug-resistant tuberculosis?
- Mexico ranks 19th and Senegal ranks 20th of 56 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of drugs for extensively drug-resistant tuberculosis. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting extensively drug-resistant tuberculosis treatment, excluding buffer stock.